Conivaptan for the treatment of hyponatremia

References

• Flear CT, Gill GV, Burn J. Hyponatraemia: mechanisms and management. Lancet2(8236), 26–31 (1981).
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am. J. Med.119(7 Suppl. 1), S30–S35 (2006).
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med.120(11 Suppl. 1), S1–S21 (2007).
   Google Scholar
• Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin. Nephrol.29(3), 282–299 (2009).
   PubMed Web of Science ®Google Scholar
• Thurman J, Halterman R, Berl T. Therapy of dysnatremia disorders. In: Therapy in Nephrology and Hypertension. Brady H, Wilcox C (Eds). Saunders, London, UK, 335–348 (2003).
   Google Scholar
• Adrogue HJ, Madias NE. Hyponatremia. N. Engl. J. Med.342(21), 1581–1589 (2000).
   PubMed Web of Science ®Google Scholar
• Mount DB. Hyponatremia: introduction. Semin. Nephrol.29(3), 175–177 (2009).
   PubMed Web of Science ®Google Scholar
• Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int.76(6), 587–589 (2009).
   PubMed Web of Science ®Google Scholar
• Miller M. Syndromes of excess antidiuretic hormone release. Crit. Care Clin.17(1), 11–23, v (2001).
   PubMed Web of Science ®Google Scholar
• Rossi NF, Cadnapaphornchai P. Disordered water metabolism: hyponatremia. Crit. Care Clin.3(4), 759–777 (1987).
   PubMed Web of Science ®Google Scholar
• Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. J. Am. Geriatr. Soc.43(12), 1410–1413 (1995).
   PubMed Web of Science ®Google Scholar
• Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med.122(9), 857–865 (2009).
   PubMed Web of Science ®Google Scholar
• Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am. J. Med.119(7 Suppl. 1), S36–S42 (2006).
   Web of Science ®Google Scholar
• Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol. Metab. Clin. North Am.30(3), 671–694, vii (2001).
   PubMed Web of Science ®Google Scholar
• Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation118(4), 410–421 (2008).
   PubMed Web of Science ®Google Scholar
• Verbalis JG. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol.29(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol. Metab. Clin. North Am.31(1), 121–140 (2002).
   PubMed Web of Science ®Google Scholar
• Mount DB. The brain in hyponatremia: both culprit and victim. Semin. Nephrol.29(3), 196–215 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med.102(2), 164–168 (1985).
   PubMed Web of Science ®Google Scholar
• Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am. J. Med.42(5), 790–806 (1967).
   PubMed Web of Science ®Google Scholar
• Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am. J. Physiol.248(3 Pt 2), H396–H402 (1985).
   Google Scholar
• Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve. Clin. J. Med.73(Suppl. 3), S24–S33 (2006).
   PubMedGoogle Scholar
• Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J. Pharmacol. Exp. Ther.316(2), 564–571 (2006).
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet371(9624), 1624–1632 (2008).
   PubMed Web of Science ®Google Scholar
• Moen MD, Keating GM. Intravenous conivaptan. Am. J. Cardiovasc. Drugs8(5), 341–348; discussion 349 (2008).
   PubMed Web of Science ®Google Scholar
• Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J. Clin. Endocrinol. Metab.82(4), 1054–1057 (1997).
   PubMed Web of Science ®Google Scholar
• Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol.16(4), 846–851 (2005).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355(20), 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol.47(8), 1615–1621 (2006).
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology37(1), 182–191 (2003).
   PubMed Web of Science ®Google Scholar
• Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin. J. Am. Soc. Nephrol.1(6), 1154–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology48(1), 204–213 (2008).
   PubMed Web of Science ®Google Scholar
• Okuno K, Taya K, Marmarou CR et al. The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. Acta Neurochirurgica102, 431–436 (2008).
   Google Scholar
• Taya K, Gulsen S, Okuno K, Prieto R, Marmarou CR, Marmarou A. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta neurochirurgica102, 425–429 (2008).
   Google Scholar
• Yamamura Y, Ogawa H, Chihara T et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science252(5005), 572–574 (1991).
   PubMed Web of Science ®Google Scholar
• Griebel G, Simiand J, Serradeil-Le Gal C et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl Acad. Sci. USA99(9), 6370–6375(2002).
   PubMed Web of Science ®Google Scholar
• Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res.170, 473–512 (2008).
   PubMed Web of Science ®Google Scholar
• Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin. Chim. Acta337(1–2), 169–172 (2003).
   PubMed Web of Science ®Google Scholar
• Hoorn E, Lindemans J, Zietse R. Hyponatremia in hospitalized patients: epidemiology, etiology and symptomatology [abstract]. J. Am. Soc. Nephrol.15561A (2004).
   Google Scholar
• Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am. J. Med. Sci.337(1), 28–36 (2009).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab.91(6), 2145–2152 (2006).
   PubMed Web of Science ®Google Scholar
• Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int.69(12), 2124–2130 (2006).
   PubMed Web of Science ®Google Scholar
• Tahara A, Tomura Y, Wada KI et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther.282(1), 301–308 (1997).
   PubMed Web of Science ®Google Scholar
• Matsuhisa A, Kikuchi K, Sakamoto K, Yatsu T, Tanaka A. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4´-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4´-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives. Chem. Pharm. Bull.47(3), 329–339 (1999).
   PubMed Web of Science ®Google Scholar
• Burnier M, Fricker AF, Hayoz D, Nussberger J, Brunner HR. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur. J. Clin. Pharmacol.55(9), 633–637 (1999).
   PubMed Web of Science ®Google Scholar
• Weber R, Pechere-Bertschi A, Hayoz D et al. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension30(5), 1121–1127 (1997).
   PubMed Web of Science ®Google Scholar
• Mao ZL, Stalker D, Keirns J. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin. Ther.31(7), 1542–1550 (2009).
   PubMed Web of Science ®Google Scholar
• Verbalis J, Bisaha J, Smith N. Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J. Am. Soc. Nephrol.15356A (abstract SA-P0254) (2004).
   Google Scholar
• Gross P, Bisaha J, Smith N. Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. J. Am. Soc. Nephrol.15355A (abstract SA-P0243) (2004).
   Google Scholar
• Ghali J, Smith N. Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia. J. Am. Soc. Nephrol.15355A (abstract SA-P0251) (2004).
   Google Scholar
• Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol.27(5), 447–457 (2007).
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin. Endocrinol. (Oxf.)69(1), 159–168 (2008).
   PubMed Web of Science ®Google Scholar
• Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. DOI: 10.1093/ndt/gfp731 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocritical Care11(1), 14–19 (2009).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation104(20), 2417–2423 (2001).
   PubMed Web of Science ®Google Scholar